Baseline characteristics
| . | Total (N = 458) . |
|---|---|
| Median age (range), y | 58 (31-65) |
| Sex, n (%) | |
| Male | 240 (52.4) |
| Female | 218 (47.6) |
| ECOG performance status, n (%) | |
| 0 | 195 (42.6) |
| 1 | 182 (39.7) |
| 2 | 62 (13.5) |
| 3 | 16 (3.5) |
| Missing | 3 (0.7) |
| M-protein type, n (%) | |
| IgG | 273 (59.6) |
| IgA | 107 (23.4) |
| Light chain | 69 (15.1) |
| IgD | 3 (0.7) |
| Nonsecretory | 6 (1.3) |
| ISS stage, n (%) | |
| I | 179 (39.1) |
| II | 166 (36.2) |
| III | 107 (23.4) |
| Missing | 6 (1.3) |
| Creatinine clearance, n (%) | |
| <60 mL/min | 70 (15.3) |
| ≥60 mL/min | 370 (80.8) |
| Missing | 18 (3.9) |
| Lactate dehydrogenase elevated, n (%) | |
| Yes | 65 (14.2) |
| No | 376 (82.1) |
| Missing | 17 (3.7) |
| High-risk cytogenetics, n (%)* | 92 (20.1) |
| . | Total (N = 458) . |
|---|---|
| Median age (range), y | 58 (31-65) |
| Sex, n (%) | |
| Male | 240 (52.4) |
| Female | 218 (47.6) |
| ECOG performance status, n (%) | |
| 0 | 195 (42.6) |
| 1 | 182 (39.7) |
| 2 | 62 (13.5) |
| 3 | 16 (3.5) |
| Missing | 3 (0.7) |
| M-protein type, n (%) | |
| IgG | 273 (59.6) |
| IgA | 107 (23.4) |
| Light chain | 69 (15.1) |
| IgD | 3 (0.7) |
| Nonsecretory | 6 (1.3) |
| ISS stage, n (%) | |
| I | 179 (39.1) |
| II | 166 (36.2) |
| III | 107 (23.4) |
| Missing | 6 (1.3) |
| Creatinine clearance, n (%) | |
| <60 mL/min | 70 (15.3) |
| ≥60 mL/min | 370 (80.8) |
| Missing | 18 (3.9) |
| Lactate dehydrogenase elevated, n (%) | |
| Yes | 65 (14.2) |
| No | 376 (82.1) |
| Missing | 17 (3.7) |
| High-risk cytogenetics, n (%)* | 92 (20.1) |
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System.
High-risk cytogenetics defined as del(17p), t(4;14), and/or t(14;16).